Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mary King

Physician Assistant Centennial, CO Physician Assistant

NPI 1245728203 CMS profile 10456150

6801 S Yosemite St, Centennial, CO 80112

Open in the dashboard

General payments

$6,026

275 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary King of Centennial, CO is reported in the CMS Open Payments database as having received $6,026 across 275 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,427 70
2024 General $988 34
2023 General $1,264 63
2022 General $982 38
2021 General $1,365 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary King
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Mary King were reported at $1,427. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Mary King Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,365 $132 $37–$438 $132
2022 $982 $155 $48–$522 $149
2023 $1,264 $167 $52–$557 $160
2024 $988 $178 $55–$600 $164
2025 $1,427 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. BioCryst US Sales Co., LLC $733 57 payments
  2. ADMA BioManufacturing LLC $557 5 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $515 24 payments
  4. CSL Behring $511 17 payments
  5. Pharming Healthcare, Inc. $354 14 payments
  6. Genzyme Corporation $316 16 payments
  7. ANI Pharmaceuticals, Inc. $312 3 payments
  8. Genentech USA, Inc. $263 13 payments
  9. Cycle Pharmaceuticals Inc $260 12 payments
  10. GlaxoSmithKline, LLC. $259 20 payments
  11. Other $1,946 94 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,634 268 payments
  2. Consulting Fee $210 2 payments
  3. Education $181 5 payments
Products named General payments · program years 2021–2025
  1. Orladeyo $763 58 payments
  2. DUPIXENT $381 17 payments
  3. PURIFIED CORTROPHIN GEL $312 3 payments
  4. TAKHZYRO $298 15 payments
  5. Xolair $251 12 payments
  6. Sajazir $249 11 payments
  7. FIRDAPSE $246 12 payments
  8. RUCONEST $229 13 payments
  9. Haegarda $210 7 payments
  10. NUCALA $172 15 payments
  11. Other $2,247 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

196

Median for Physician Assistant: 241

Drug cost

$6,045,734

Median for Physician Assistant: $4,110

Branded share of claims

73.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ruconest C1 Esterase Inhibitor, Recomb Brand 42 $3,593,778
Firazyr Icatibant Acetate Brand 25 $1,107,285
Orladeyo Berotralstat Hydrochloride Brand 16 $658,876
Haegarda C1 Esterase Inhibitor Brand 24 $581,031
Dupixent Syringe Dupilumab Brand 25 $95,847
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $7,739
Hydroxychloroquine Sulfate Generic 29 $1,038
Montelukast Sodium Generic 23 $140

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$760,186

Of which drugs: $729,336

Medicare patients

179

Average age 64

Services billed

21,141

138 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 51%
High blood pressure 45%
Depression 32%
Osteoporosis 22%
COPD 19%
Ischemic heart disease 18%
Diabetes 16%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 36 6,450 $239,463
Injection, immune globulin (bivigam), 500 mg J1556 Office 11 2,000 $115,983
Injection, omalizumab, 5 mg J2357 Office 11 2,071 $61,294
Infusion, normal saline solution , 1000 cc J7030 Office 12 42 $87
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 23 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $294
$294 — —
TAKHZYRO
  • Takeda Pharmaceuticals U.S.A., Inc. $105
$105 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $53
  • GENZYME CORPORATION $43
$96 25 —
RUCONEST
  • Pharming Healthcare, Inc. $96
$96 42 —
XOLAIR
  • Novartis Pharmaceuticals Corporation $76
  • Genentech USA, Inc. $15
$91 — 2,071

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

275 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record